Model
Edge
Regeneron Pharmaceuticals, Inc.
REGN
Filing Type
10-Q
Filing Date
10/30/2024
Updated
10/31/24, 5:16 AM
Filing
10-Q
Earnings Release
Exhibits
10-Q
Q3
EX-10.1
AMENDMENT NO. 3 TO MASTER AGREEMENT BETWEEN REGN AND ALNYLAM
EX-31.1
CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A)
EX-31.2
CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A)
EX-32
CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C SECTION 1350